Michael Hamilton
Scientist Vividion Therapeutics
Seminars
Tuesday 8th September 2026
Disruption of the RAS-PI3Kα Interaction Provides Enhanced Efficacy in Combination Mutant KRAS Targeting Therapies
9:30 am
- Targeting oncogenic RAS-PI3Kα signaling with small molecules that selectively block the RAS-PIK3CA interaction while preserving homeostatic PI3Kα function, improving tolerability in ways traditional active site inhibitors cannot
- Enhancing antitumor activity by combining selective RAS-PIK3CA inhibition with MAPK pathway agents, achieving dramatic efficacy improvements in preclinical RAS driven cancer models
- Countering intrinsic & adaptive resistance to direct mutant KRAS inhibitors through blockage of WT RAS-driven activation of the PI3K/AKT pathway
